VLRX - Valeritas Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.5800
-0.0800 (-4.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6600
Open1.6900
Bid0.0000 x 900
Ask1.7400 x 2900
Day's Range1.5600 - 1.6960
52 Week Range1.5600 - 33.2000
Volume324,780
Avg. Volume555,165
Market Cap11.309M
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today data from its preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device have been accepted for a poster presentation at the annual CannMed Conference in Pasadena, CA, on September 23-24, 2019. Pharmacokinetic Study of Subcutaneous Infusion of Cannabinoid (CBD) Isolate in Dogs via the   h-Patch™ Wearable Device. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia held in Rome, Italy, on October 14-16, 2019. On August 5th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of continuous subcutaneous infusion of apomorphine (Apo) delivered via its proprietary h-Patch™ wearable drug delivery device. The wearable h-Patch™ represents a patient-friendly subcutaneous delivery mechanism for Apo providing the benefits of a full 24-hour infusion of low dose Apo to eliminate “off” periods and improve motor status without tolerability issues seen with subcutaneous injections.

  • GlobeNewswire

    Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch™ technology. “We are very excited by the data from this PK study and the potential our h-Patch™ technology has in providing peak plasma levels equivalent to oral administration despite delivering only a fraction of the amount of CBD,” said John Timberlake, President and Chief Executive Officer of Valeritas.

  • GlobeNewswire

    Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today an oral presentation to be given at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit held in Boston, MA, on September 10-12, 2019. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 1,665 shares of Valeritas’ common stock to 4 newly-hired employees, with a grant date of August 28, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed. The stock options were granted as inducements material to the new employees entering into employment with Valeritas in accordance with NASDAQ Listing Rule 5635(c)(4).

  • GlobeNewswire

    Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that a randomized controlled trial comparing the delivery of U-100 Regular Human Insulin (RHI) by V-Go versus delivery of Rapid Acting Insulin (RAI) by V-Go in patients with type 2 diabetes has met the primary A1c (blood sugar levels) endpoint.

  • GlobeNewswire

    Valeritas Announces Second Quarter 2019 Financial Results

    BRIDGEWATER, N.J., Aug. 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire

    Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device. Valeritas’ h-Patch™ is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas.

  • GlobeNewswire

    Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device. The Company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model.

  • GlobeNewswire

    Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it will release financial results for the second quarter of 2019 after the close of trading on Thursday, August 8, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population

    BRIDGEWATER, N.J., July 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced.

  • GlobeNewswire

    Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced it has filed a “Special 510(k): Device Modification” submission with the FDA  that includes using regular human insulin (RHI) in the device. A small peer-reviewed study published in Clinical Diabetes in October 2016 concluded that use of RHI administered by V-Go resulted in improved glycemic control with an estimated annual direct pharmacy costs savings exceeding $3,000 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070587/). “Valeritas is focused on solutions that are both highly effective and help patients reduce their costs in managing diabetes.

  • GlobeNewswire

    Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced today it has surpassed a significant milestone of selling more than 20 million V-Go insulin delivery devices in the United States. “There are millions of patients with type 2 diabetes on insulin therapy in the United States, and the majority are not meeting their A1c or blood sugar goal,” said John Timberlake, President and Chief Executive Officer of Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional positive data from the VERDICT study was presented at the American Diabetes Association's 79th Scientific Sessions held in San Francisco, California. “Insulin therapy is often intensified utilizing a stepwise approach of adding one injection at a time due to the increased burden and complexity associated with basal-bolus therapy,” said Trisha Zeidan, MD, Principal Investigator of the VERDICT Study and affiliated with Premier Physician Network, Bull Family Diabetes Center.

  • GlobeNewswire

    Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced today it will participate in this year’s American Diabetes Association’s (ADA) 79th Scientific Sessions at the Moscone Center in San Francisco, CA, on June 7-11, 2019. Additionally, Valeritas reiterated its second quarter 2019 revenue guidance of $7.4 million to $7.6 million and its 2019 annual revenue guidance of $31.0 million to $34.0 million. Also, the Company now expects to end the second quarter with $27 million in cash and cash equivalents vs. the original estimate of $25 million with the Company’s current cash position now allowing it to operate into February 2020, assuming no additional capital or non-dilutive financing.

  • GlobeNewswire

    American Diabetes Association Includes “Disposable Patch-Like Device,” such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced the inclusion by the American Diabetes Association (ADA) of the use of a “disposable patch-like device” for insulin delivery in the new Diabetes Technology chapter of ADA’s annual Standards of Medical Care in Diabetes for 2019, published in Diabetes Care. The inclusion in this year’s Standards of Care marks the first time such a device has been incorporated in ADA’s current clinical practice recommendations.

  • GlobeNewswire

    Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional data from the VERDICT study at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. “The VERDICT study demonstrates that significantly more patients achieved better control and attained improved quality metrics.  We will continue to partner with clinicians to improve patient outcomes and quality of care delivered using V-Go as a standard way to deliver basal-bolus insulin therapy,” said John Timberlake, President and Chief Executive Officer of Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • GlobeNewswire

    Valeritas Announces Reverse Stock Split

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that its Board of Directors has declared a 1-for-20 reverse stock split of the Company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 20, 2019. At that time, each 20 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares that would result from the reverse stock split will be settled in cash.

  • GlobeNewswire

    Valeritas Exhibits at Taking Control of Your Diabetes Conferences

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it is exhibiting at three Taking Control of Your Diabetes (TCOYD) conferences and health fairs. Valeritas is also exhibiting at TCOYD conferences on October 12, 2019, in San Diego, CA and November 2, 2019, in Charlotte, NC.

  • GlobeNewswire

    Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance

    BRIDGEWATER, N.J., May 09, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire

    Valeritas Expects First Quarter Revenue of $6.4 million

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced today it expects to report revenue of approximately $6.4 million for the first quarter ended March 31, 2019. In addition, Valeritas does not expect any significant changes from its first quarter 2019 guidance that it released on March 5, 2019, as the Company will achieve all metrics it provided guidance on for the quarter. Valeritas intends to report its full first quarter 2019 financial results on May 9, 2019.

  • GlobeNewswire

    Valeritas to Present at Upcoming Investor Conferences

    BRIDGEWATER, N.J., April 29, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14%

    BRIDGEWATER, N.J., April 26, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced.

  • GlobeNewswire

    Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it will release financial results for the first quarter of 2019 after the close of trading on Thursday, May 9, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.